In Vitro Evaluation of a Novel Derivative Combination Antimicrobial Ceftriaxone + Sulbactam + EDTA against Pan-resistant Gram-negative Bacteria at a 1,000-bedded Tertiary Care Teaching Hospital in Northern India
Journal of Medical Academics
The global emergence of antimicrobial resistance among gram-negative (GN) species is a major public health concern. The emergence of pan-resistant superbugs has further led to a serious threat to global public health security. The infections with these bacterial strains are associated with prolonged hospitalization, disseminated infections, and mortality. Newer therapeutic strategies are urgently needed to be explored to avoid the problems of developing further resistance. Aim and objective:
... ting of a novel antibiotic combination regimen to investigate the effectiveness in in vitro sensitivity testing against pan-resistant superbugs. Materials and methods: In this prospective cross-sectional study, all pan-resistant, non-repeat, consecutive gram-negative bacteria identified through Vitek 2 compact (Biomerieux, France) automated microbiology system from intensive care unit, acute medical wards, and acute surgical wards were selected. And a novel derivative combination antimicrobial ceftriaxone 30 μg + sulbactam 15 μg + EDTA (CSE) was tested on panresistant microbes for possible susceptibility through Kirby-Bauer disk diffusion on Mueller-Hinton agar. Results: Ceftriaxone + sulbactam + EDTA was found effective in vitro against pan-resistant GN bacterial strains (56.94%). Among these panresistant GN bacterial strains, pan-resistant Klebsiella and Proteus strains were found highly susceptible (91% and 87%, respectively) to CSE. Discussion: Ceftriaxone + sulbactam + EDTA can be effective in treating pan-resistant GN bacterial strains as evident by in vitro susceptibility testing. Multiple centers involving both laboratories and patient care centers are required to coordinate and perform such types of studies to further augment the present knowledge and developing therapeutic options for these resistant superbugs. 12 The present study aimed toward in vitro evaluation of a novel derivative combination molecule ceftriaxone + sulbactam + EDTA (CSE) against pan-resistant superbugs at a 1,000-bedded tertiarycare teaching hospital in northern India.